GlassScriptPhysician profile
Thomas G Olbrych
NPI 1538151089
$363.98
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $74.41 · 2021: $72.01 · 2022: $16.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $94.09 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $45.67 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $26.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.15 | 2019 | |
| Sobi, INC | $21.93 | 2021 | |
| Abbvie INC. | $21.36 | 2021 | |
| Allergan, INC. | $20.84 | 2019 | |
| Genentech USA, INC. | $16.41 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.68 | 2019 | |
| Insmed, INC. | $15.65 | 2021 | |
| Genzyme Corporation | $13.07 | 2021 | |
| Gilead Sciences, INC. | $12.61 | 2020 | |
| Vivus LLC | $12.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.21 | 2020 | |
| Philips North America LLC | $11.03 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Olbrych listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.